Brief: Xencor Reports Third Quarter 2021 Financial Results And Announces Encouraging Preliminary Data From Ongoing Phase 1 Study Of Potency-Reduced Il15-FC Cytokine, Xmab306

Xencor

08/11/2021 21:07

Nov 8 (Reuters) - Xencor Inc  XNCR.O :
    * XENCOR REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND
ANNOUNCES ENCOURAGING PRELIMINARY DATA FROM ONGOING PHASE 1
STUDY OF POTENCY-REDUCED IL15-FC CYTOKINE, XMAB306
    * Q3 LOSS PER SHARE $0.69
    * Q3 REVENUE $19.7 MILLION
    * Q3 EARNINGS PER SHARE VIEW $-0.65, REVENUE VIEW $19.0
MILLION --
REFINITIV IBES DATA
    * EXCEPTIONAL NK CELL EXPANSION OF 40- TO 100-FOLD INCREASES
COMPARED TO BASELINE, WITH GOOD TOLERABILITY TO DATE, HAS BEEN
OBSERVED

Source text for Eikon:  ID:nBwXmzrla 
Further company coverage:  XNCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))